PERELMAN RONALD O

SEC source: 0001140361-22-041084 · form4.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Owned through wholly owned corporations

Disclosed balance after: 41,676,969

F1 · price: The shares were sold to RCH Holdings Six Inc. by Perelman Trust Company, LLC, over which MacAndrews & Forbes Incorporated ("M&F") exercises voting control, in exchange for cash consideration of $45,463.52. Mr. Perelman is the sole stockholder of M&F. The transaction was effectuated to implement certain philanthropic endeavors for Mr. Perelman.

F2 · balance_after: Of the 41,676,969 shares of Class A Common Stock reported herein, (i) 36,470,036 shares of Class A Common Stock are owned by M&F or its wholly owned subsidiaries; and (ii) 5,206,933 shares of Class A Common Stock are owned by RCH Holdings Five Inc.

SEC source: 0000950142-21-004124 · es210212345_4-perelman.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 36,519,212

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). The ROP Revocable Trust is also the sole stockholder of Thirty Six East Corporation ("Thirty Six East"). M&F Group, MFV and Thirty Six East hold the securities described above. (cont'd on FN 2)

F2 · ownership.nature: (cont'd from FN 1) Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group, MFV and Thirty Six East may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of the role of Rich Nelson, director of the Issuer, as Executive Vice President Corporate and Business Development of Vericast and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001209191-20-065042 · doc4.xml · nonDerivative · entry 2

PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Owned through wholly owned corporations

Disclosed balance after: 46,223,321

F1 · kind: The shares were transferred to a holding company in which The ROP Revocable Trust dated 1/9/2018 and The Ronald O. Perelman 2020 Trust each own 50% of the shares called RCH Holdings Five Inc., in exchange for cash consideration of $7,640,068 and notes with aggregate principal amount of $43,293,717 payable to subsidiaries of MacAndrews & Forbes Incorporated ("M&F"). Mr. Perelman is the sole trustee of The Revocable Trust dated 1/9/2018 and is the settlor of The Ronald O. Perelman 2020 Trust. The transaction was effectuated to implement certain estate planning matters for Mr. Perelman.

F1 · price: The shares were transferred to a holding company in which The ROP Revocable Trust dated 1/9/2018 and The Ronald O. Perelman 2020 Trust each own 50% of the shares called RCH Holdings Five Inc., in exchange for cash consideration of $7,640,068 and notes with aggregate principal amount of $43,293,717 payable to subsidiaries of MacAndrews & Forbes Incorporated ("M&F"). Mr. Perelman is the sole trustee of The Revocable Trust dated 1/9/2018 and is the settlor of The Ronald O. Perelman 2020 Trust. The transaction was effectuated to implement certain estate planning matters for Mr. Perelman.

F2 · balance_after: Of the 46,223,321 shares of Class A Common Stock reported herein, (i) 36,470,036 shares of Class A Common Stock are owned by M&F or its wholly-owned subsidiaries; (ii) 4,546,352 shares of Class A Common Stock are owned by Perelman Trust Company, LLC, over which M&F exercises voting control; and (iii) 5,206,933 shares of Class A Common Stock are owned by RCH Holdings Five Inc.

SEC source: 0001209191-20-065042 · doc4.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Owned through RCH Holdings Five Inc.

Disclosed balance after: 46,223,321

F1 · kind: The shares were transferred to a holding company in which The ROP Revocable Trust dated 1/9/2018 and The Ronald O. Perelman 2020 Trust each own 50% of the shares called RCH Holdings Five Inc., in exchange for cash consideration of $7,640,068 and notes with aggregate principal amount of $43,293,717 payable to subsidiaries of MacAndrews & Forbes Incorporated ("M&F"). Mr. Perelman is the sole trustee of The Revocable Trust dated 1/9/2018 and is the settlor of The Ronald O. Perelman 2020 Trust. The transaction was effectuated to implement certain estate planning matters for Mr. Perelman.

F1 · price: The shares were transferred to a holding company in which The ROP Revocable Trust dated 1/9/2018 and The Ronald O. Perelman 2020 Trust each own 50% of the shares called RCH Holdings Five Inc., in exchange for cash consideration of $7,640,068 and notes with aggregate principal amount of $43,293,717 payable to subsidiaries of MacAndrews & Forbes Incorporated ("M&F"). Mr. Perelman is the sole trustee of The Revocable Trust dated 1/9/2018 and is the settlor of The Ronald O. Perelman 2020 Trust. The transaction was effectuated to implement certain estate planning matters for Mr. Perelman.

F2 · balance_after: Of the 46,223,321 shares of Class A Common Stock reported herein, (i) 36,470,036 shares of Class A Common Stock are owned by M&F or its wholly-owned subsidiaries; (ii) 4,546,352 shares of Class A Common Stock are owned by Perelman Trust Company, LLC, over which M&F exercises voting control; and (iii) 5,206,933 shares of Class A Common Stock are owned by RCH Holdings Five Inc.

F1 · ownership.nature: The shares were transferred to a holding company in which The ROP Revocable Trust dated 1/9/2018 and The Ronald O. Perelman 2020 Trust each own 50% of the shares called RCH Holdings Five Inc., in exchange for cash consideration of $7,640,068 and notes with aggregate principal amount of $43,293,717 payable to subsidiaries of MacAndrews & Forbes Incorporated ("M&F"). Mr. Perelman is the sole trustee of The Revocable Trust dated 1/9/2018 and is the settlor of The Ronald O. Perelman 2020 Trust. The transaction was effectuated to implement certain estate planning matters for Mr. Perelman.

SEC source: 0001140361-20-028743 · form4.xml · derivative · entry 2

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1

Underlying: Class A common stock · 625,000 shares

Expires 2020-12-23

F2 · kind: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On December 17, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash.

F2 · price: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On December 17, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash.

F2 · balance_after: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On December 17, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash.

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001140361-20-028743 · form4.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 36,606,212

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001140361-20-028037 · form4.xml · derivative · entry 2

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1

Underlying: Class A common stock · 625,000 shares

Expires 2020-12-23

F2 · kind: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On December 10, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash.

F2 · price: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On December 10, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash.

F2 · balance_after: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On December 10, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash.

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001140361-20-028037 · form4.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 35,981,212

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001140361-20-026446 · form4.xml · derivative · entry 2

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1

Underlying: Class A common stock · 625,000 shares

Expires 2020-12-23

F2 · kind: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On November 24, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash.

F2 · price: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On November 24, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash.

F2 · balance_after: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On November 24, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash.

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001140361-20-026446 · form4.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 35,356,212

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001209191-20-054669 · doc4.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · 10% owner · Former Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 8,871,313

F1 · ownership.nature: Mr. Perelman is the sole beneficiary and trustee of The ROP Revocable Trust dated 1/9/2018 (the "Trust"), which directly holds 122,728 shares of Common Stock. The Trust is also the sole stockholder of MacAndrews & Forbes Incorporated, which is the sole stockholder, directly or indirectly, of each of SGMS Acquisition Corporation, RLX Holdings Two LLC, SGMS Acquisition Two LLC, SGMS Acquisition Three LLC and MacAndrews & Forbes Group, LLC, which hold the remaining securities described above. Mr. Perelman does not own any shares of Common Stock directly. On October 12, 2020, SGMS Acquisition Corporation, RLX Holdings Two LLC, SGMS Acquisition Two LLC and SGMS Acquisition Three LLC sold an aggregate of 1,964,285 shares of Common Stock pursuant to the previously disclosed Stock Purchase Agreement by and among SGMS Acquisition Corporation, RLX Holdings Two LLC, SGMS Acquisition Two LLC, SGMS Acquisition Three LLC, MacAndrews & Forbes Group, LLC and Pivot Buyer LLC.

SEC source: 0001209191-20-054282 · doc4.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · 10% owner · Former Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 10,835,598

F1 · ownership.nature: Mr. Perelman is the sole beneficiary and trustee of The ROP Revocable Trust dated 1/9/2018 (the "Trust"), which directly holds 122,728 shares of Common Stock. The Trust is also the sole stockholder of MacAndrews & Forbes Incorporated, which is the sole stockholder, directly or indirectly, of each of SGMS Acquisition Corporation, RLX Holdings Two LLC, SGMS Acquisition Two LLC, SGMS Acquisition Three LLC and MacAndrews & Forbes Group, LLC, which hold the remaining securities described above. Mr. Perelman does not own any shares of Common Stock directly. On October 7, 2020, SGMS Acquisition Corporation, RLX Holdings Two LLC and SGMS Acquisition Two LLC sold an aggregate of 2,499,999 shares of Common Stock pursuant to the previously disclosed Stock Purchase Agreement by and among SGMS Acquisition Corporation, RLX Holdings Two LLC, SGMS Acquisition Two LLC, SGMS Acquisition Three LLC, MacAndrews & Forbes Group, LLC and Pivot Buyer LLC.

SEC source: 0001209191-20-052475 · doc4.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · 10% owner · Former Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 13,318,493

F1 · ownership.nature: Mr. Perelman is the sole beneficiary and trustee of The ROP Revocable Trust dated 1/9/2018 (the "Trust"), which directly holds 105,624 shares of Common Stock. The Trust is also the sole stockholder of MacAndrews & Forbes Incorporated, which is the sole stockholder, directly or indirectly, of each of SGMS Acquisition Corporation, RLX Holdings Two LLC, SGMS Acquisition Two LLC, SGMS Acquisition Three LLC and MacAndrews & Forbes Group, LLC, which hold the remaining securities described above. Mr. Perelman also directly owns 17,104 shares of Common Stock. On September 30, 2020, SGMS Acquisition Corporation and RLX Holdings Two LLC sold an aggregate of 4,700,000 shares of Common Stock pursuant to the previously disclosed Stock Purchase Agreement by and among SGMS Acquisition Corporation, RLX Holdings Two LLC, SGMS Acquisition Two LLC, SGMS Acquisition Three LLC, MacAndrews & Forbes Group, LLC and Pivot Buyer LLC.

SEC source: 0001209191-20-052359 · doc4.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · 10% owner · Former Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 18,018,493

F1 · ownership.nature: Mr. Perelman is the sole beneficiary and trustee of The ROP Revocable Trust dated 1/9/2018 (the "Trust"), which directly holds 105,624 shares of Common Stock. The Trust is also the sole stockholder of MacAndrews & Forbes Incorporated, which is the sole stockholder, directly or indirectly, of each of SGMS Acquisition Corporation, RLX Holdings Two LLC, SGMS Acquisition Two LLC, SGMS Acquisition Three LLC and MacAndrews & Forbes Group, LLC, which hold the remaining securities described above. Mr. Perelman also directly owns 17,104 shares of Common Stock. On September 28, 2020, SGMS Acquisition Corporation, RLX Holdings Two LLC and SGMS Acquisition Two LLC sold an aggregate of 9,417,062 shares of Common Stock pursuant to the previously disclosed Stock Purchase Agreement by and among SGMS Acquisition Corporation, RLX Holdings Two LLC, SGMS Acquisition Two LLC, SGMS Acquisition Three LLC, MacAndrews & Forbes Group, LLC and Pivot Buyer LLC.

SEC source: 0001209191-20-050743 · doc4.xml · derivative · entry 6

PERELMAN RONALD O · CIK 0001186472 · Director · Executive Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,372 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Represents vesting of the restricted stock units granted on June 10, 2020 in connection with the conclusion of Mr. Perelman's service as a director on September 16, 2020 as described above. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis.

F5 · derivative.exercise_date: Represents vesting of the restricted stock units granted on June 10, 2020 in connection with the conclusion of Mr. Perelman's service as a director on September 16, 2020 as described above. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis.

F5 · derivative.expiration_date: Represents vesting of the restricted stock units granted on June 10, 2020 in connection with the conclusion of Mr. Perelman's service as a director on September 16, 2020 as described above. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis.

SEC source: 0001209191-20-050743 · doc4.xml · derivative · entry 5

PERELMAN RONALD O · CIK 0001186472 · Director · Executive Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,783 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Represents vesting of the remaining restricted stock units granted on June 12, 2019 in connection with the conclusion of Mr. Perelman's service as a director on September 16, 2020 as described above. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis.

F4 · derivative.exercise_date: Represents vesting of the remaining restricted stock units granted on June 12, 2019 in connection with the conclusion of Mr. Perelman's service as a director on September 16, 2020 as described above. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis.

F4 · derivative.expiration_date: Represents vesting of the remaining restricted stock units granted on June 12, 2019 in connection with the conclusion of Mr. Perelman's service as a director on September 16, 2020 as described above. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis.

SEC source: 0001209191-20-050743 · doc4.xml · derivative · entry 4

PERELMAN RONALD O · CIK 0001186472 · Director · Executive Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,394 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Represents vesting of the remaining restricted stock units granted on June 13, 2018 in connection with the conclusion of Mr. Perelman's service as a director on September 16, 2020 as described above. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis.

F3 · derivative.exercise_date: Represents vesting of the remaining restricted stock units granted on June 13, 2018 in connection with the conclusion of Mr. Perelman's service as a director on September 16, 2020 as described above. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis.

F3 · derivative.expiration_date: Represents vesting of the remaining restricted stock units granted on June 13, 2018 in connection with the conclusion of Mr. Perelman's service as a director on September 16, 2020 as described above. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis.

SEC source: 0001209191-20-050743 · doc4.xml · derivative · entry 3

PERELMAN RONALD O · CIK 0001186472 · Director · Executive Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,555 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Represents vesting of the remaining restricted stock units granted on June 19, 2017 in connection with the conclusion of Mr. Perelman's service as a director on September 16, 2020 in connection with the transactions provided for in the Stock Purchase Agreement. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis.

F2 · derivative.exercise_date: Represents vesting of the remaining restricted stock units granted on June 19, 2017 in connection with the conclusion of Mr. Perelman's service as a director on September 16, 2020 in connection with the transactions provided for in the Stock Purchase Agreement. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis.

F2 · derivative.expiration_date: Represents vesting of the remaining restricted stock units granted on June 19, 2017 in connection with the conclusion of Mr. Perelman's service as a director on September 16, 2020 in connection with the transactions provided for in the Stock Purchase Agreement. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis.

SEC source: 0001209191-20-050743 · doc4.xml · nonDerivative · entry 2

PERELMAN RONALD O · CIK 0001186472 · Director · Executive Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 27,435,554

F1 · ownership.nature: Mr. Perelman is the sole beneficiary and trustee of The ROP Revocable Trust dated 1/9/2018 (the "Trust"), which directly holds 105,624 shares of common stock. The Trust is also the sole stockholder of MacAndrews & Forbes Incorporated, which is the sole stockholder, directly or indirectly, of each of SGMS Acquisition Corporation, RLX Holdings Two LLC, SGMS Acquisition Two LLC, SGMS Acquisition Three LLC and MacAndrews & Forbes Group, LLC, which hold the remaining securities described above. On September 16, 2020, SGMS Acquisition Corporation, RLX Holdings Two LLC, SGMS Acquisition Two LLC, SGMS Acquisition Three LLC and MacAndrews & Forbes Group, LLC sold an aggregate of 9,375,806 shares of Common Stock pursuant to a Stock Purchase Agreement with Pivot Buyer LLC (the "Stock Purchase Agreement").

SEC source: 0001209191-20-050743 · doc4.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · Director · Executive Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,104

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000750004-20-000108 · wf-form4_159259881921710.xml · derivative · entry 3

PERELMAN RONALD O · CIK 0001186472 · Director · Executive Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,555

Underlying: Common Stock · 1,555 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Represents vesting of one-fourth of restricted stock units granted on June 19, 2017. The balance of the award is scheduled to vest on June 19, 2021. Each unit converts into a share of common stock on a one-for-one basis.

F2 · derivative.exercise_date: Represents vesting of one-fourth of restricted stock units granted on June 19, 2017. The balance of the award is scheduled to vest on June 19, 2021. Each unit converts into a share of common stock on a one-for-one basis.

F2 · derivative.expiration_date: Represents vesting of one-fourth of restricted stock units granted on June 19, 2017. The balance of the award is scheduled to vest on June 19, 2021. Each unit converts into a share of common stock on a one-for-one basis.

SEC source: 0000750004-20-000108 · wf-form4_159259881921710.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · Director · Executive Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,518

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000750004-20-000098 · wf-form4_159225316152578.xml · derivative · entry 5

PERELMAN RONALD O · CIK 0001186472 · Director · Executive Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,371

Underlying: Common Stock · 4,339 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Represents vesting of one-fourth of restricted stock units granted on June 15, 2016. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis.

F3 · derivative.exercise_date: Represents vesting of one-fourth of restricted stock units granted on June 15, 2016. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis.

F3 · derivative.expiration_date: Represents vesting of one-fourth of restricted stock units granted on June 15, 2016. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis.

SEC source: 0000750004-20-000098 · wf-form4_159225316152578.xml · nonDerivative · entry 2

PERELMAN RONALD O · CIK 0001186472 · Director · Executive Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,963

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000750004-20-000098 · wf-form4_159225316152578.xml · derivative · entry 4

PERELMAN RONALD O · CIK 0001186472 · Director · Executive Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,394

Underlying: Common Stock · 697 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Represents vesting of one-fourth of restricted stock units granted on June 13, 2018. The balance of the award is scheduled to vest in equal installments of 697 shares on each of June 13, 2021 and June 13, 2022. Each unit converts into a share of common stock on a one-for-one basis.

F2 · derivative.exercise_date: Represents vesting of one-fourth of restricted stock units granted on June 13, 2018. The balance of the award is scheduled to vest in equal installments of 697 shares on each of June 13, 2021 and June 13, 2022. Each unit converts into a share of common stock on a one-for-one basis.

F2 · derivative.expiration_date: Represents vesting of one-fourth of restricted stock units granted on June 13, 2018. The balance of the award is scheduled to vest in equal installments of 697 shares on each of June 13, 2021 and June 13, 2022. Each unit converts into a share of common stock on a one-for-one basis.

SEC source: 0000750004-20-000098 · wf-form4_159225316152578.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · Director · Executive Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,624

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000750004-20-000083 · wf-form4_159199391229280.xml · derivative · entry 4

PERELMAN RONALD O · CIK 0001186472 · Director · Executive Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,783

Underlying: Common Stock · 1,927 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Represents vesting of one-fourth of restricted stock units granted on June 12, 2019. The balance of the award is scheduled to vest in three installments on June 12, 2021 (1,928 shares), June 12, 2022 (1,927 shares) and June 12, 2023 (1,928 shares). Each unit converts into a share of common stock on a one-for-one basis.

F3 · derivative.exercise_date: Represents vesting of one-fourth of restricted stock units granted on June 12, 2019. The balance of the award is scheduled to vest in three installments on June 12, 2021 (1,928 shares), June 12, 2022 (1,927 shares) and June 12, 2023 (1,928 shares). Each unit converts into a share of common stock on a one-for-one basis.

F3 · derivative.expiration_date: Represents vesting of one-fourth of restricted stock units granted on June 12, 2019. The balance of the award is scheduled to vest in three installments on June 12, 2021 (1,928 shares), June 12, 2022 (1,927 shares) and June 12, 2023 (1,928 shares). Each unit converts into a share of common stock on a one-for-one basis.

SEC source: 0000750004-20-000083 · wf-form4_159199391229280.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · Director · Executive Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,927

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000750004-20-000083 · wf-form4_159199391229280.xml · derivative · entry 3

PERELMAN RONALD O · CIK 0001186472 · Director · Executive Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,372

Underlying: Common Stock · 8,372 shares

Expires not disclosed

F2 · derivative.exercise_price: The restricted stock units are scheduled to vest in four equal annual installments beginning on June 10, 2021. Each unit converts into a share of common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units are scheduled to vest in four equal annual installments beginning on June 10, 2021. Each unit converts into a share of common stock on a one-for-one basis.

F2 · derivative.expiration_date: The restricted stock units are scheduled to vest in four equal annual installments beginning on June 10, 2021. Each unit converts into a share of common stock on a one-for-one basis.

SEC source: 0001140361-20-011442 · form4.xml · derivative · entry 2

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1

Underlying: Class A common stock · 625,000 shares

Expires 2020-12-23

F2 · kind: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On May 12, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash.

F2 · price: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On May 12, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash.

F2 · balance_after: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On May 12, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash.

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001140361-20-011442 · form4.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 34,731,212

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001140361-20-004007 · form4.xml · derivative · entry 2

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1

Underlying: Class A common stock · 1,250,000 shares

Expires 2020-12-23

F2 · kind: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On February 25, 2020, the Issuer exercised its right to have M&F Group purchase 1,250,000 shares of Common Stock for a total purchase price of $2,000,000 in cash.

F2 · price: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On February 25, 2020, the Issuer exercised its right to have M&F Group purchase 1,250,000 shares of Common Stock for a total purchase price of $2,000,000 in cash.

F2 · balance_after: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On February 25, 2020, the Issuer exercised its right to have M&F Group purchase 1,250,000 shares of Common Stock for a total purchase price of $2,000,000 in cash.

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001140361-20-004007 · form4.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 34,106,212

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001140361-20-001599 · form4.xml · derivative · entry 2

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1

Underlying: Class A common stock · 1,250,000 shares

Expires 2020-12-23

F2 · kind: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On January 28, 2020, the Issuer exercised its right to have M&F Group purchase 1,250,000 shares of Common Stock for a total purchase price of $2,000,000 in cash.

F2 · price: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On January 28, 2020, the Issuer exercised its right to have M&F Group purchase 1,250,000 shares of Common Stock for a total purchase price of $2,000,000 in cash.

F2 · balance_after: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On January 28, 2020, the Issuer exercised its right to have M&F Group purchase 1,250,000 shares of Common Stock for a total purchase price of $2,000,000 in cash.

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001140361-20-001599 · form4.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 32,856,212

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001140361-20-000401 · form4.xml · derivative · entry 2

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1

Underlying: Class A common stock · 1,250,000 shares

Expires 2020-12-23

F2 · kind: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On January 7, 2020, the Issuer exercised its right to have M&F Group purchase 1,250,000 shares of Common Stock for a total purchase price of $2,000,000 in cash.

F2 · price: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On January 7, 2020, the Issuer exercised its right to have M&F Group purchase 1,250,000 shares of Common Stock for a total purchase price of $2,000,000 in cash.

F2 · balance_after: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On January 7, 2020, the Issuer exercised its right to have M&F Group purchase 1,250,000 shares of Common Stock for a total purchase price of $2,000,000 in cash.

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001140361-20-000401 · form4.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 31,606,212

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001140361-19-023102 · form4.xml · derivative · entry 2

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1

Underlying: Class A common stock · 365,472 shares

Expires 2026-12-23

F3 · kind: In consideration for the commitment of M&F Group under the Letter Agreement, the Issuer issued M&F Group a warrant (the "Warrant") to purchase 365,472 shares of Common Stock, exercisable at a price of $1.84, which is 115% of the option price under the Letter Agreement. The Warrant is exercisable until December 23, 2026.

F3 · price: In consideration for the commitment of M&F Group under the Letter Agreement, the Issuer issued M&F Group a warrant (the "Warrant") to purchase 365,472 shares of Common Stock, exercisable at a price of $1.84, which is 115% of the option price under the Letter Agreement. The Warrant is exercisable until December 23, 2026.

F3 · balance_after: In consideration for the commitment of M&F Group under the Letter Agreement, the Issuer issued M&F Group a warrant (the "Warrant") to purchase 365,472 shares of Common Stock, exercisable at a price of $1.84, which is 115% of the option price under the Letter Agreement. The Warrant is exercisable until December 23, 2026.

F2 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001140361-19-023102 · form4.xml · derivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1

Underlying: Class A common stock · 6,250,000 shares

Expires 2020-12-23

F1 · kind: On December 23, 2019, MacAndrews & Forbes Group LLC ("M&F Group") entered into a letter agreement (the "Letter Agreement"), with vTv Therapeutics Inc. (the "Issuer") for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million.

F1 · price: On December 23, 2019, MacAndrews & Forbes Group LLC ("M&F Group") entered into a letter agreement (the "Letter Agreement"), with vTv Therapeutics Inc. (the "Issuer") for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million.

F1 · balance_after: On December 23, 2019, MacAndrews & Forbes Group LLC ("M&F Group") entered into a letter agreement (the "Letter Agreement"), with vTv Therapeutics Inc. (the "Issuer") for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million.

F2 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001140361-19-022838 · form4.xml · derivative · entry 2

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1

Underlying: Class A common stock · 1,369,863 shares

Expires 2020-09-26

F2 · kind: On September 26, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.46. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On December 18, 2019, the Issuer exercised its right to have M&F Group purchase 1,369,863 shares of Common Stock for a total purchase price of $2,000,000 in cash.

F2 · price: On September 26, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.46. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On December 18, 2019, the Issuer exercised its right to have M&F Group purchase 1,369,863 shares of Common Stock for a total purchase price of $2,000,000 in cash.

F2 · balance_after: On September 26, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.46. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On December 18, 2019, the Issuer exercised its right to have M&F Group purchase 1,369,863 shares of Common Stock for a total purchase price of $2,000,000 in cash.

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001140361-19-022838 · form4.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 30,356,212

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001140361-19-021508 · form4.xml · derivative · entry 2

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1

Underlying: Class A common stock · 1,369,863 shares

Expires 2020-09-26

F2 · kind: On September 26, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.46. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On November 26, 2019, the Issuer exercised its right to have M&F Group purchase 1,369,863 shares of Common Stock for a total purchase price of $2,000,000 in cash.

F2 · price: On September 26, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.46. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On November 26, 2019, the Issuer exercised its right to have M&F Group purchase 1,369,863 shares of Common Stock for a total purchase price of $2,000,000 in cash.

F2 · balance_after: On September 26, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.46. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On November 26, 2019, the Issuer exercised its right to have M&F Group purchase 1,369,863 shares of Common Stock for a total purchase price of $2,000,000 in cash.

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001140361-19-021508 · form4.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 28,986,349

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001140361-19-020346 · form4.xml · derivative · entry 2

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1

Underlying: Class A common stock · 1,369,863 shares

Expires 2020-09-26

F2 · kind: On September 26, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.46. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On November 12, 2019, the Issuer exercised its right to have M&F Group purchase 1,369,863 shares of Common Stock for a total purchase price of $2,000,000 in cash.

F2 · price: On September 26, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.46. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On November 12, 2019, the Issuer exercised its right to have M&F Group purchase 1,369,863 shares of Common Stock for a total purchase price of $2,000,000 in cash.

F2 · balance_after: On September 26, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.46. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On November 12, 2019, the Issuer exercised its right to have M&F Group purchase 1,369,863 shares of Common Stock for a total purchase price of $2,000,000 in cash.

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001140361-19-020346 · form4.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 27,616,486

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001140361-19-019008 · form4.xml · derivative · entry 2

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1

Underlying: Class A common stock · 1,369,863 shares

Expires 2020-09-26

F2 · kind: On September 26, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.46. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On October 24, 2019, the Issuer exercised its right to have M&F Group purchase 1,369,863 shares of Common Stock for a total purchase price of $2,000,000 in cash.

F2 · price: On September 26, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.46. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On October 24, 2019, the Issuer exercised its right to have M&F Group purchase 1,369,863 shares of Common Stock for a total purchase price of $2,000,000 in cash.

F2 · balance_after: On September 26, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.46. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On October 24, 2019, the Issuer exercised its right to have M&F Group purchase 1,369,863 shares of Common Stock for a total purchase price of $2,000,000 in cash.

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001140361-19-019008 · form4.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 26,246,623

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0000950157-19-001131 · form4.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 36,793,768

F1 · price: The transaction was executed in multiple trades at prices ranging from $20.30 to $20.51. The price reported above reflects the weighted average purchase price. Details regarding aggregated purchase transactions will be provided upon request by the Commission staff, the issuer or a security holder of the issuer.

F2 · ownership.nature: Mr. Perelman is the sole beneficiary and trustee of The ROP Revocable Trust dated 1/9/2018 (the "Trust"), which directly holds 88,032 shares of common stock. The Trust is also the sole stockholder of MacAndrews & Forbes Incorporated, which is the sole stockholder, directly or indirectly, of each of SGMS Acquisition Corporation, RLX Holdings Two LLC, SGMS Acquisition Two LLC, SGMS Acquisition Three LLC and MacAndrews & Forbes Group, LLC, which hold the remaining securities described above.

SEC source: 0000950157-19-001106 · form4.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 36,743,768

F1 · price: The transaction was executed in multiple trades at prices ranging from $20.47 to $20.98. The price reported above reflects the weighted average purchase price. Details regarding aggregated purchase transactions will be provided upon request by the Commission staff, the issuer or a security holder of the issuer.

F2 · ownership.nature: Mr. Perelman is the sole beneficiary and trustee of The ROP Revocable Trust dated 1/9/2018 (the "Trust"), which directly holds 88,032 shares of common stock. The Trust is also the sole stockholder of MacAndrews & Forbes Incorporated, which is the sole stockholder, directly or indirectly, of each of SGMS Acquisition Corporation, RLX Holdings Two LLC, SGMS Acquisition Two LLC, SGMS Acquisition Three LLC and MacAndrews & Forbes Group, LLC, which hold the remaining securities described above.

SEC source: 0001140361-19-017447 · form4.xml · derivative · entry 4

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1

Underlying: Class A common stock · 1,369,863 shares

Expires 2020-09-26

F2 · kind: On September 26, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.46. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On September 27, 2019, the Issuer exercised its right to have M&F Group purchase 1,369,863 shares of Common Stock for a total purchase price of $2,000,000 in cash.

F2 · price: On September 26, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.46. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On September 27, 2019, the Issuer exercised its right to have M&F Group purchase 1,369,863 shares of Common Stock for a total purchase price of $2,000,000 in cash.

F2 · balance_after: On September 26, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Company's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.46. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On September 27, 2019, the Issuer exercised its right to have M&F Group purchase 1,369,863 shares of Common Stock for a total purchase price of $2,000,000 in cash.

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of M&F Group. M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.